Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.52 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25848744 | 0.93 | TLR2 (0.56) | TLR2TNFSIRT2KMT2A | |
| SCHEMBL25835749 | 0.83 | TLR2 (0.60) | TLR2SIRT2 | |
| SCHEMBL26044431 | 0.81 | TLR2 (0.56) | TLR2TNFKMT2A | |
| SCHEMBL25848358 | 0.79 | TLR2 (0.43) | TLR2SIRT2 | |
| SCHEMBL25848801 | 0.76 | TLR2 (0.57) | TLR2KMT2A | |
| SCHEMBL25835723 | 0.75 | TLR2 (0.61) | TLR2SIRT2 | |
| SCHEMBL2244979 | 0.75 | KMT2A (0.62) | TLR2SIRT2KMT2A | |
| SCHEMBL2244741 | 0.75 | KMT2A (0.62) | TLR2SIRT2KMT2A | |
| SCHEMBL31282864 | 0.75 | KMT2A (0.62) | TLR2SIRT2KMT2A | |
| SCHEMBL30020633 | 0.75 | TLR2 (0.53) | TLR2TNFSIRT2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | TLR2 3599/4885TNF 3906/4885SIRT2 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.